REFERENCES


References


17. FDA, 1995, Center for drug evaluation and research, Guidance for industry Immediate release solid oral dosage forms. Scale-up and post-approval changes Chemistry, manufacturing and controls, in vitro dissolution testing, and in vivo bioequivalence documentation (SUPAC-IR), November 1995


31 Khan MZI, Dissolution testing for sustained or controlled release oral dosage forms and correlation with in vivo data: challenges and opportunities. Int J Pharm., 1996, 140, 131-143.


References


References


154 Klein S, Rudolph MW, Dressman JB, Drug release characteristics of different Mesalazine products using USP apparatus 3 to simulate passage through the GI tract Dissolution Tech., 2002, 9(4), 6-13


Bogner RH, Bioavailability and bioequivalence of extended release oral dosage forms US Pharmacist, 1997, 22 (Suppl), 3-12


183 Dahlqvist R, Billing B, Miners JO, Birkett DJ, Nonlinear metabolic disposition of theophylline. Ther Drug Monit, 1984, 6, 290-297.


References


283 WinNonlin-Pro™, Scientific Consulting Inc., Cary, North Carolina, USA


296. Dressman JB, Johann Wolfgang Goethe-Universitat, Germany (Personal Communication)


References


References


382. Rao BE, Raghuveer CMR, Srivastava, HPLC determination of Rifampicin, Pyrazinamide and Isoniazid in single and combined dosage form. Indian Drugs, 1992, 29(9), 412-415


410. Singh S, Mariappan TT, Sharda N, Singh B, Degradation of rifampicin, isoniazid and pyrazinamide from prepared mixtures and marketed single and


413 Gharbo SA, Cognion MM, Williamson MJ, Modified dissolution method for rifampin, Drug Dev Ind Pharm, 1989, 15/2, 331-335


References


454. Schall R, Muller FO, Duursema L, Groenewoud G, Hundt HK, Middle MV, Mogilnicka EM, Swart KJ, Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol Arzneim. Forsch., 1995, 45(11), 1236-1239.


References


